Evaluation of a program of pharmaceutical counseling for French patients on oral anticoagulant therapy

  • C. Roseau
  • C. Richard
  • S. Renet
  • C. Kowal
  • L. Eliahou
  • A. Rieutord
  • M.-C. ChaumaisEmail author
Research Article


Background Oral anticoagulants are widely used for treatment and prevention of thromboembolic diseases. We set up a pharmaceutical counseling program for both direct oral anticoagulant and vitamin K antagonist drugs in our hospital in 2015. Objective Evaluate patient satisfaction and the evolution of their knowledge throughout the pharmaceutical counseling program on anticoagulants and identify knowledge variability factors. Setting Cardiology Inpatient Unit from the University Antoine Béclère Hospital, France. Methods Evaluation was based on data collection of patients surveyed between 2015 and 2018. Inpatients in the cardiology department on oral anticoagulants were eligible. The learning process was designed to enhance patient knowledge and understanding based on 10 cognitive or self-management skills, relating to the optimization of oral anticoagulant therapy management. It consisted in 2 face-to-face interviews during hospitalization and 2 additional phone interviews one and six months after discharge. The median patient score was evaluated at each step of the process as well as the mean score for each item from the global population. A sub-analysis was run on the less well-acquired skills in order to identify risk factors for limited knowledge. The association between those factors and the level of knowledge (score ≥ 7 or < 7) was assessed using Chi square test followed by multivariate analysis. Main outcome measure Patient knowledge of anticoagulation therapy depending on specific factors. Results Of the 880 patients eligible for pharmaceutical counseling, 319 entered the process and 102 completed it. Median knowledge scores were 8/10 and 9/10 after the first and the final interviews respectively with a significant improvement (p = 0.0003). The least well-acquired items at each step were surveillance and under-dosing management. The sub-analysis showed the use of vitamin K antagonist to be linked to an enhanced understanding related to treatment surveillance (p = 0.029). Patients suffering from atrial fibrillation were found to have a worse understanding of under-dosing management (p = 0.013). Finally, patients evaluated the process as helpful and suitable for their conditions. Conclusion Pharmaceutical counseling is appropriate for patients, improving and maintaining knowledge of oral anticoagulants. Our evaluation highlights the need to focus on patient-specific profiles to reach a satisfactory level of knowledge.


Direct oral anticoagulants DOACs France Patient education Program evaluation Therapy related knowledge Vitamin-K-antagonists 



We thank S. Ghouti-Baxter for the English review.


The set-up of the pharmaceutical counseling process was partially funded by a Pulsaction grant supported by Boehringer Ingelheim.

Conflicts of interest

C. Kowal and A. Rieutord reports non-financial support from Pfizer. M-C Chaumais reports non-financial support from Bayer and grants from Boehringer Ingelheim. The other authors report no conflicts of interest.


  1. 1.
    Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316:2115–25.CrossRefGoogle Scholar
  2. 2.
    2005 - Les événements indésirables graves liés aux soins .pdf [Internet]. [cited 2019 Jul 22]. Available from:
  3. 3.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.CrossRefGoogle Scholar
  4. 4.
    Keijsers CJPW, Leendertse AJ, Faber A, Brouwers JRBJ, de Wildt DJ, Jansen PAF. Pharmacists’ and general practitioners’ pharmacology knowledge and pharmacotherapy skills. J Clin Pharmacol. 2015;55:936–43.CrossRefGoogle Scholar
  5. 5.
    Croft H, Gilligan C, Rasiah R, Levett-Jones T, Schneider J. Current trends and opportunities for competency assessment in pharmacy education–a literature review. Pharmacy. 2019;7:67.CrossRefGoogle Scholar
  6. 6.
    Wright DFB, Anakin MG, Duffull SB. Clinical decision-making: An essential skill for 21st century pharmacy practice. Res Social Adm Pharm. 2019;15:600–6.CrossRefGoogle Scholar
  7. 7.
    Ahmed NO, Osman B, Abdelhai YM, El-Hadiyah TMH. Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan. Int J Clin Pharm. 2017;39:769–73.CrossRefGoogle Scholar
  8. 8.
    Falamić S, Lucijanić M, Hadžiabdić MO, Marušić S, Bačić Vrca V. Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. Int J Clin Pharm. 2018;Google Scholar
  9. 9.
    Marcatto LR, Sacilotto L, Tavares LC, Facin M, Olivetti N, Strunz CMC, et al. Pharmaceutical care increases time in therapeutic range of patients with poor quality of anticoagulation with warfarin. Front Pharmacol. 2018;9:1052.CrossRefGoogle Scholar
  10. 10.
    Pouyet V, Abassade P, Cador R. Evaluation about patient’s knowledge on their direct oral anticoagulants treatment. Ann Cardiol Angeiol (Paris). 2017;66:269–74.CrossRefGoogle Scholar
  11. 11.
    Amara W, Larsen TB, Sciaraffia E, Hernández Madrid A, Chen J, Estner H, et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace. 2016;18:151–5.CrossRefGoogle Scholar
  12. 12.
    Zdyb EG, Courtney DM, Malik S, Schmidt MJ, Lyden AE. Impact of discharge anticoagulation education by emergency department pharmacists at a tertiary academic medical center. J Emerg Med. 2017;53:896–903.CrossRefGoogle Scholar
  13. 13.
    Keita I, Aubin-Auger I, Lalanne C, Aubert J-P, Chassany O, Duracinsky M, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017;11:1625–34.CrossRefGoogle Scholar
  14. 14.
    Weernink MGM, Vaanholt MCW, Groothuis-Oudshoorn CGM, von Birgelen C, IJzerman MJ, van Til JA. Patients’ priorities for oral anticoagulation therapy in non-valvular atrial fibrillation: a multi-criteria decision analysis. Am J Cardiovasc Drugs. 2018;18:493–502.Google Scholar
  15. 15.
    Rolls CA, Obamiro KO, Chalmers L, Bereznicki LRE. The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation. Cardiovasc Ther. 2017;35:e12304.CrossRefGoogle Scholar
  16. 16.
    Cao H, Wu J, Zhang J. Outcomes of warfarin therapy managed by pharmacists via hospital anticoagulation clinic versus online anticoagulation clinic. Int J Clin Pharm. 2018;40:1072–7.CrossRefGoogle Scholar
  17. 17.
    Décret n° 2017–884 du 9 mai 2017 modifiant certaines dispositions réglementaires relatives aux recherches impliquant la personne humaine. 2017–884 mai, 2017.Google Scholar
  18. 18.
    Barbier E, Chaumais M-C, Desnoyer A, Rieutord A, Haddad R, Vignand-Courtin C. Dispositif de formation d’une équipe pharmaceutique à la consultation d’accompagnement d’un patient sous traitement anticoagulant oral. Pédagogie Médicale. 2013;14:269–83.CrossRefGoogle Scholar
  19. 19.
    Barbier E, Chaumais M-C, Launay-Vacher G, Rieutord A, Haddad R. Formation de l’équipe pharmaceutique aux consultations antivitamines K (AVK): une expérience de blended-learning à l’hôpital. Journal de Pharmacie Clinique. 2014;33:125–32.Google Scholar
  20. 20.
    entretien-pharmaceutique-avk_assurance-maladie.pdf [Internet]. [cited 2018 Dec 7]. Available from:
  21. 21.
    Antonio Hernandez Madrid, Tatjana S. Potpara, Nikolaos Dagres, Jian Chen, Torben B. Larsen, Heidi Estner, et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2015;18:463–467.Google Scholar
  22. 22.
    Viola R, Fekete H, Csoka I. Patients’ knowledge on oral anticoagulant treatment in Hungary. Int J Clin Pharm. 2017;39:1265–72.CrossRefGoogle Scholar
  23. 23.
    Lane DA, Langman CM, Lip GYH, Nouwen A. Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. J Psychosom Res. 2009;66:203–10.CrossRefGoogle Scholar
  24. 24.
    Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174:30–42.CrossRefGoogle Scholar
  25. 25.
    Sun G-W, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49:907–16.CrossRefGoogle Scholar
  26. 26.
    Kaufman BG, Kim S, Pieper K, Allen LA, Gersh BJ, Naccarelli GV, et al. Disease understanding in patients newly diagnosed with atrial fibrillation. Heart. 2018;104:494–501.CrossRefGoogle Scholar
  27. 27.
    Pourafkari L, Baghbani-Oskouei A, Taban-Sadeghi M, Salamzadeh V, Ghaffari S, Savadi-Oskouei S, et al. Factors Influencing various aspects of patients’ knowledge of oral anticoagulation. J Cardiovasc Pharmacol. 2018;71:174–9.CrossRefGoogle Scholar
  28. 28.
    Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LRE. Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey. Int J Clin Pract. 2018;72(3):e13072.CrossRefGoogle Scholar
  29. 29.
    Raparelli V, Proietti M, Cangemi R, Lip GYH, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209–18.Google Scholar
  30. 30.
    Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Lip GYH. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety. 2017;16:1051–62.CrossRefGoogle Scholar
  31. 31.
    Pourafkari L, Baghbani-Oskouei A, Taban-Sadeghi M, Salamzadeh V, Ghaffari S, Savadi-Oskouei S, et al. Factors influencing various aspects of patients’ knowledge of oral anticoagulation. J Cardiovasc Pharmacol. 2018;71:174–9.CrossRefGoogle Scholar
  32. 32.
    Macedo AF, Bell J, McCarron C, Conroy R, Richardson J, Scowcroft A, et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink. Thromb Res. 2015;136:250–60.CrossRefGoogle Scholar
  33. 33.
    Obamiro KO, Chalmers L, Bereznicki LRE. Development and validation of an oral anticoagulation knowledge tool (AKT). PLoS ONE. 2016;11:e0158071.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.AP-HP, Service de pharmacie, DHU Thorax InnovationHôpital Antoine BéclèreClamart CedexFrance
  2. 2.Service de PharmacieGroupe Hospitalier Paris Saint-JosephParisFrance
  3. 3.Univ. Paris–Sud, Faculté de PharmacieUniversité Paris-SaclayChâtenay MalabryFrance
  4. 4.AP-HP, Service de pharmacieHôpital Albert ChenevierCreteilFrance
  5. 5.AP-HP, Service de cardiologieHôpital Antoine BéclèreClamartFrance
  6. 6.INSERM UMR_S 999Hôpital Marie LannelongueLe Plessis RobinsonFrance

Personalised recommendations